secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2022-03-24T23:59:59+00:00
Accession:  0001104659-22-037193
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical reports FY2021 record revenue of $63.1M, net loss of $44.0M; DFD-29 Phase 3 underway
--------------------------------------------------------------------------------

- Record net product revenues of $63.1M in FY2021, up 42% from $44.5M in FY2020.
- Net loss attributable to common stockholders of $44.0M ($4.32/share) vs net income of $5.3M ($0.58/share) in FY2020.
- Non-GAAP adjusted EBITDA positive at $2.9M; non-GAAP net loss of $16.9M ($1.66/share).
- Cash and equivalents $49.1M at Dec 31, 2021, up from $8.2M a year ago, boosted by IPO proceeds.
- Dosed first patient in Phase 3 for DFD-29 for rosacea; received $10M milestone from Maruho; acquired VYNE MST franchise for $20M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465922037193/0001104659-22-037193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465922037193/tm2210106d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-037193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer